

<b>Area</b>	Diagnostics
<b>Headquarter</b>	Tartu, Estonia
<b>Countries of operation</b>	Estonia
<b>Founding year</b>	2018
<b>Status</b>	On the market

<b>Incubator programme</b>	EIT Health Digital Sandbox Programme
<b>Licenses</b>	Healthcare L04685, CE-marked medical device (IVD)
<b>Approvals</b>	Republic of Estonia Health Board
<b>Revenue (last yr)</b>	N/A
<b>Funds raised</b>	€300k
<b>Currently raising:</b>	€1.5M


## Summary

Antegenes is a biotechnology and healthcare company developing and implementing innovative genetic tests. We have developed genetics-based risk assessment tests for four cancers (breast prostate colorectal cancer and melanoma genetic risk tests) based on polygenic risk score (PRS) technology which assess patient's personal cancer risks and include clinical recommendations for further treatment and selection of health behaviours.

Antegenes has also developed a high-level bioinformatics software system AnteModel - a software system that is used to run the pipelines of genetic data analysis to prepare patient reports for all genetic tests on offer.

### USE OF FUNDS

■ Marketing ■ Sales



Interested? Get in touch